Until now, individuals experiencing SARS COV-2 (Covid-19) had no way to alleviate their symptoms. At Xpress Urgent Care, we treat Covid-19 with a monoclonal antibody production treatment (Regen-CoV) to help reduce patients’ symptoms. The COVID-19 Treatment received FDA Approval (Emergency use authorization EUA) in November of 2020. Monoclonal antibody treatment is covered by most insurance plans and is also available for the uninsured.
Monoclonal antibodies are lab-created proteins that mimic the ones humans produce to fight viruses and diseases. The antibodies defend the body by blocking Covid-19 viruses from attaching to and entering human cells. The treatment, developed by Regeneron, is shown to reduce the risk of hospitalization or death in 70 percent of patients.
Monoclonal Antibody Therapy is FDA Approval (EUA Emergency Use Authorization)- Fast, Safe, and Effective.
The Food and Drug Administration approved Regen-CoV for emergency use in November of 2020. The Regen-CoV treatment has been tested extensively by Regeneron in a clinical trial setting. Regeneron reported 70 percent of patients who took Regen-CoV supported their immune system, leading to the recovery of Covid-19 symptoms.
A Covid-19 diagnosis can be stressful, especially to individuals who experience pre-existing health conditions. Regen-CoV reduces symptoms that can make a recovery difficult. If you have tested positive for Covid-19 or want to see if you qualify for Regen-CoV, please complete this form.
Frequently Asked Questions
Xpress Urgent Care is thrilled to offer Orange County, California, and surrounding areas access to Covid-19 antibody therapy infusion centers. With four convenient locations in Tustin, Stanton, Costa Mesa, and Huntington Beach. Our services are also convenient to Santa Ana, Orange, Irvine, Westminster, Garden Grove, Anaheim, and Newport Beach.
Click here to find an infusion center near you.
Patients receiving a single dose of Regen-CoV will undergo an intravenous infusion. It is available at Xpress Urgent Care to Covid-19 patients struggling with symptoms. Patients receiving Regen-CoV should hydrate well and dress comfortably. The treatment can last up to 2.5 hours.
The following medical conditions or other factors may place adults and pediatric patients (age 12-17 years and weighing at least 40kg) at higher risk for progression to severe COVID-19:
- Older age (for example, age 65 years or older)
- Obesity or being overweight (for example, BMI > 25)
- Chronic kidney disease
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease or hypertension
- Chronic lung disease
- Sickle cell disease
- Neurodevelopmental disorder
These pre-existing conditions that put you at high risk may qualify you for treatment. However, It is ultimately up to the healthcare provider to decide if you need treatment of mild to moderate Covid-19 symptoms. Let your health care provider know if you are progressing to severe Covid-19 symptoms.
If you have received a COVID-19 vaccine, you might still be eligible for Regen-CoV monoclonal antibody therapy. Wait 90 days after the Regen-CoV treatment and consult a health care professional before getting a Covid-19 vaccine. If you are unsure if you qualify, check in online now and speak with a health care provider.
Yes, select children may be eligible for monoclonal antibody therapy. Those who are 12 years of age or older and at high risk for progressing moderate Covid-19 symptoms may be eligible. Schedule a consultation appointment with a healthcare provider to see if Regen-CoV is right for your child.
At this time, our Regen-CoV treatment is covered by most insurance plans and for those who are uninsured. Before any treatment occurs, one of the staff members will let you know if you have any deductibles or fees. To see a complete list of our insurance partners, click here.
Speak with your health care professional about potential infusion reactions such as allergic reactions. Consult this Medical News Today resource for information about casirivimab and imdevimab (known as Regen-CoV). Additionally, Stanford Medicine released this article, including a testimony from a patient who received Regen-CoV treatment.